Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			5-day change	1st Jan Change
74.13 ^USD	-0.64%		-8.95%	-4.73%

05-15	Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses	RE
05-15	Kymera Therapeutics, Inc. Announces Presentations And Clinical Data For KT-621 Oral STAT6 Degrader	CI

Transcript : Kymera Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09

Published on 05/12/2026 at 06:20 pm BST - Modified on 05/12/2026 at 07:35 pm BST

S&P Capital IQ

Presenter Speech
Tazeen Ahmad (Analysts)

[Audio Gap] chatting with Kymera Therapeutics. Up here on stage, we've got a couple of members from the management team. We've got Bruce Jacobs, who's, of

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Kymera Therapeutics, Inc.

05-15	Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses	RE
05-15	Kymera Therapeutics, Inc. Announces Presentations And Clinical Data For KT-621 Oral STAT6 Degrader	CI
05-12	Kymera Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09:20 AM
05-06	Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target	MT
05-05	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, A First-In-Class, Oral Irf5 Degrader, At Digestive Disease Week	CI
04-30	Kymera Therapeutics, Inc., Q1 2026 Earnings Call, Apr 30, 2026
04-30	Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises	MT
04-30	Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-30	Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss	MT
04-30	Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M	MT
04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI
04-09	Kymera to Receive $45 Million Milestone Payment as Gilead Exercises Option to License KT-200	MT
04-09	Kymera Therapeutics announces Gilead Sciences' option exercise to license KT-200, oral CDK2 molecular glue degrader development candidate	RE
04-09	Kymera Therapeutics and Gilead Sciences Enter License Agreement for Kt-200 with $45 Million Milestone Payment	CI